{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"Grade 1"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade 2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Grade 3"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Grade 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"The following hematology laboratory parameters were assessed: hemoglobin high, hemoglobin low, leukocytes high, leukocytes low, lymphocytes high, lymphocytes low, neutrophils low and platelets low. Laboratory abnormality events were graded according to NCI CTCAE v 4.03 (grade 1=mild, grade 2=moderate, grade 3= severe and grade 4= life-threatening). Participants with any hematology parameter meeting CTCAE grade 1 to 4 were reported.","groups":[{"description":"Participants received SEA-BCMA 1600 mg IV q2wk on Day 1 and 15 of each 28-day cycle, dexamethasone 40 mg orally or as an IV infusion on Day 1, 8, 15, and 22 and pomalidomide 4 mg orally, daily from Day 1 to 21 of each of each 28-day cycle. Participants received treatment until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first.","id":"OG000","title":"Part D: SEA-BCMA 1600 mg, Pomalidomide and Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All treated participants analysis set included all treated participants who received any amount of SEA-BCMA.","reportingStatus":"POSTED","timeFrame":"From first dose of the study treatment (Day 1) up to 30 days after the last dose of study treatment up to 19 months (maximum follow up of 20 months)","title":"Number of Participants With Maximum Laboratory Toxicity Grade, by NCI-CTCAE v4.03- Hematology: Part D","type":"PRIMARY","unitOfMeasure":"Participants"}